Background
AML
DISEASE, ACUTE MYELOID LEUKEMIA, AML
Acute myeloid leukemia (AML) is a heterogeneous and aggressive hematopoietic malignancy with a great variation in disease outcomes. Despite great advances in chemotherapy and hematopoietic stem cell transplantation (HSCT), there is still up to 35–45% of patients being refractory to treatments or relapsed [Homoharringtonine, extracted from the herb 